

**AMERICAN VIETNAMESE BIOTECH INC**  
**INTERIM FINANCIAL STATEMENTS**

**The first 6 months of the fiscal year ending December 31, 2025**

**has been reviewed by**

**NHAN TAM VIET AUDITING COMPANY LIMITED**

## INDEX

Content	Page
Report of the Board of Directors	2-4
Report the results of the review work	5-6
The interim financial statements have been reviewed	7-43
<i>Balance sheet as of June 30, 2025</i>	7-10
<i>Report on interim business results for the first 6 months of the fiscal year ending December 31, 2025</i>	11
<i>Interim cash flow report for the first 6 months of the fiscal year ending December 31, 2025</i>	12-13
<i>Notes to the interim financial statements for the first 6 months of the fiscal year ending December 31, 2025</i>	14-43

## **REPORT OF THE BOARD OF DIRECTORS**

The Board of Directors of American VietNameese Biotech INC (hereinafter referred to as the "Company") presents its report together with the audited interim financial statements for the first 6 months of the fiscal year ending December 31, 2025.

### **Company Overview**

American VietNameese Biotech INC was established under Business Registration Certificate No.3800237998 First issued by the Department of Planning and Investment of Ho Chi Minh City on August 26, 2002. During its operation, the Company has changed its business registration certificate 24 times. The 24rd change in the business registration certificate of a joint stock company was issued on August 17, 2025.

*Charter capital according to the 24rd Business Registration Certificate: VND 1,311,056,500,000*  
*Actual contributed capital as of June 30, 2025: VND 1,311,056,500,000*

### **Headquarters:**

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City, Vietnam.

Phone: 0651.3.889034

Fax: 0651.3.889032

Tax code: 3 8 0 0 2 3 7 9 9 8

### **Financial situation and business operations**

The Company's interim financial position as of June 30, 2025, interim results of operations and interim cash flows for the first 6 months of the fiscal year ended December 31, 2025 are presented in the Financial Statements attached to this report (from page 07 to page 43).

### **Events occurring during and after the reporting period**

- American VietNameese Biotech INC ("AMV") with many years of experience in the medical field: providing machinery and equipment systems, supplying consumables,... Facing the increasing demand for health care services, cancer screening and home health care, learning from the infusion center model - built and operated according to Japan's international safety standards - specializing in providing drug, vitamin, protein, therapy and water infusion services to improve patient health, is gradually becoming a popular trend in many countries such as Japan, the US, Thailand. However, in Vietnam, this model is still quite new and has not been widely deployed. At the same time, after reviewing and evaluating the overall mobile examination vehicle project, investment project, joint venture linking medical image archiving and transmission systems (PACS system) with hospitals that the company previously pursued, it did not meet expectations as expected. Therefore, the company boldly divested all or part of those projects, the Company has determined a strategy to strongly develop the clinic and infusion center model in the coming time. This business strategy was approved at the 2024 Annual General Meeting of Shareholders. At present, the Company is continuing to carry out the necessary procedures to put into operation a chain of clinics across 34 provinces and cities nationwide, with the expectation of providing early and reliable diagnostic testing at the most cost-effective level through its network of testing centers.

- Resolution of the Board of Directors No. 0601/2025/NQ-HĐQT dated January 6, 2025 and Resolution of the Board of Directors No. 1701/2025/NQ-HĐQT dated January 17, 2025 on receiving the transfer of VND 204,227,000,000 of contributed capital at Phu Tho Provincial General Hospital, from Sara Vietnam Joint Stock Company. The transfer value from Sara Vietnam Joint Stock Company under contract No. 01/2025/HDCN/SARA-VIETMY dated February 15, 2025 is VND 204,227,000,000. Up to now, the Company has paid the entire amount of VND 204,227,000,000. However, according to Resolution of the Board of Directors No. 1604/2025/NQ-HĐQT dated April 16, 2025, the Company



## AMERICAN VIETNAMESE BIOTECH INC

### BOARD OF DIRECTORS' REPORT (next)

decided to withdraw capital early from Phu Tho Provincial General Hospital, the capital withdrawal plan is from 2025 to 2028. Up to now, the Hospital has transferred 17,5 billion to the company.

In addition to the above events, the Company's Board of Directors confirms that no other events have occurred up to the date of this report that have not been considered for adjustment of figures or disclosed in the Financial Statements.

#### **Board of Directors and Management**

Members of the Board of Directors, Board of Supervisors and Board of Management of the Company during the period and up to the date of this report include:

##### ***Board of Directors***

Full name	Position	Appointed/ Removed
Mr. Nakatani Yoshitaka	Chairman	
Ms. Dang Nhi Nuong	Member	
Mr. Le Khanh Nguyen	Member	

##### ***Board of Control***

Full name	Position	Appointed/ Removed
Ms. Le Thi Huong	Head of The Control Board	
Ms. Nguyen Huong Giang	Member	
Mr. Le Huu Tri	Member	Appointed on 29/7/2025
Ms. Vu Thu Thuy	Member	Removed on 29/7/2025

##### ***Board of Directors***

Full name	Position	Appointed/ Removed
Ms. Dang Nhi Nuong	Director	

##### ***Chief Accountant***

Full name	Appointed/ Removed
Mr. Dang Thi Thanh Tuyen	Appointed on 11/6/2025
Ms. Le Thi Viet Ha	Removed on 11/6/2025

##### **Auditor**

Nhan Tam Viet Auditing Company Limited has audited the Interim Financial Statements for the first 6 months of the fiscal year ending December 31, 2025.

##### **Confirmation from the Board of Directors**

The Company's Board of Directors is responsible for preparing the Interim Financial Statements which give a true and fair view of the interim financial position, the interim results of operations and the interim cash flows of the Company during the period. In preparing the Interim Financial Statements, the Company's Board of Directors undertakes to comply with the following requirements:

- Establish and maintain internal controls that the Company's management determines are necessary to enable the preparation and presentation of interim financial statements that are free from material misstatement, whether due to fraud or error;
- Select suitable accounting policies and apply them consistently;
- Make judgements and estimates that are reasonable and prudent;

## AMERICAN VIETNAMESE BIOTECH INC

### BOARD OF DIRECTORS' REPORT (next)

- State whether the applicable accounting standards have been followed, and whether there are any material departures that need to be disclosed and explained in the interim financial statements;
- Prepare and present interim financial statements in compliance with Vietnamese Accounting Standards, Enterprise Accounting Regime and legal regulations related to the preparation and presentation of interim financial statements;
- Prepare the interim financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Board of Directors is responsible for ensuring that proper accounting records are kept which disclose with reasonable accuracy at any time the financial position of the Company and that the interim financial statements comply with the applicable State regulations. At the same time, it is responsible for safeguarding the assets of the Company and taking reasonable steps to prevent and detect fraud and other irregularities.

The Company's Board of Directors is committed that the Interim Financial Statements have fairly and fairly reflected the financial position of the Company as at June 30, 2025, the results of its operations and its cash flows for the first 6 months of the fiscal year ended December 31, 2025, in accordance with Vietnamese Accounting Standards, the Vietnamese Enterprise Accounting System and in compliance with legal regulations related to the preparation and presentation of Interim Financial Statements.

#### Other commitments

Due to certain objective reasons, the Company failed to fulfill its obligation to disclose the audited financial statements for 2024 within the prescribed deadline. Consequently, the Company's shares were suspended from trading under Decision No. 153/QĐ-SGDHN dated March 17, 2025 of the Hanoi Stock Exchange. The Company has subsequently complied with its disclosure obligations by publishing the audited financial statements for 2024. On June 2, 2025, the Company's shares were reclassified to restricted trading status under Decision No. 681/QĐ-SGDHN due to late submission of the report, and further placed under control status under Decision No. 682/QĐ-SGDHN dated June 2, 2025 as the auditor issued a qualified opinion on the consolidated financial statements for 2023 and 2024. The Company is committed to fully complying with disclosure obligations within the statutory deadlines and implementing measures to remedy the above situation.

In addition to the above issue, the Board of Directors commits that the Company complies with Decree 155/2020/ND-CP dated December 31, 2020 guiding corporate governance applicable to public companies and the Company does not violate the obligation to disclose information as prescribed in Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance guiding information disclosure on the stock market.

Ho Chi Minh City, August 28, 2025

On behalf of the Board of Directors,



**Dang Nhi Nuong**





Kết nối - Phát triển

CÔNG TY TNHH KIỂM TOÁN NHÂN TÂM VIỆT  
NHANTAMVIET AUDITING COMPANY

Number : 3007.01.01/2025/BCTC-NTV2

## REPORT ON REVIEW RESULTS

About Interim Financial Report

First 6 months of the fiscal year ending December 31, 2025

Dear : Shareholders, Board of Directors, Management  
American VietNameese Biotech INC

We have reviewed the accompanying interim financial statements of American VietNameese Biotech INC, prepared on August 28, 2025 from page 08 to page 43, including the interim balance sheet as at 30 June 2025, the interim income statement, the interim cash flow statement for the first 6 months of the financial year ended 31 December 2025 and the notes to the interim financial statements.

### Responsibilities of the Board of Directors

Board of Directors American VietNameese Biotech INC be responsible for the preparation and fair presentation of the interim financial statements in accordance with Vietnamese accounting standards, accounting regimes and legal regulations related to the preparation and presentation of interim financial statements and be responsible for the internal control that the Board of Directors determines is necessary to ensure the preparation and presentation of interim financial statements that are free from material misstatement, whether due to fraud or error.

### Auditor's Responsibilities

Our responsibility is to express a conclusion on the interim financial statements based on our review. We conducted our review in accordance with Vietnamese Standard on Review Engagements No. 2410 - Review of interim financial information performed by the independent auditor of the entity.

A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Vietnamese Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### Basis of audit conclusion except

- We were unable to observe the cash count on December 31, 2024, with a cash balance of VND 290,950,121, as we had not been appointed as the auditor at that time. Accordingly, we do not express an opinion on the accuracy, existence, and completeness of cash as at that date.
- Certain associates were established but have not yet formed or possess insignificant assets to support their business operations. The capital contributions to these associates amounted to VND 46,200,000,000 (Note V.12b). Based on the audit procedures performed, we have not obtained sufficient appropriate audit evidence to assess the reasonableness of these investments or their impact on the interim financial statements for the six-month period of the financial year ending December 31, 2025.
- The Company has invested in and installed medical equipment and the RIS-PACS medical imaging storage and transmission software system under lease and cooperation contracts with hospitals and medical centers, with total investment costs as at June 30, 2025 amounting to VND 80,256,761,457 (of which VND 59,564,895,987 was handed over to hospitals for use and VND 20,691,865,470 has not yet been handed over). At certain hospitals, revenue has been generated; however, due to the lack of specific and consistent guidelines on the settlement of diagnostic imaging services based on the PACS system, the Company does not have a reliable basis to fully determine the economic benefits arising from the aforementioned leasing and cooperation arrangements. Nevertheless, the Company has recognized depreciation expenses for the portion of assets handed over in its business results, with accumulated

Trụ Sở Chính:

Tầng 2, tòa nhà Platinum Residences, số 6 Nguyễn Công Hoan,  
Phường Ngọc Khánh, Quận Ba Đình, Thành phố Hà Nội, Việt Nam

5

[T] (84-24) 3761 3399  
[W] www/vpaudit.vn

[F] (84-24) 3761 5599  
[E] vpa@ntva.vn

Chi nhánh tại Hà Nội:

Số 12 Phố Mê Trì Hạ, P. Mê Trì, Q. Nam Từ Liêm, TP. Hà Nội

Chi nhánh tại TP. Hồ Chí Minh:

98 Vũ Tông Phan, P. An Phú, Q. 2, TP. Hồ Chí Minh



## REPORT ON REVIEW RESULTS (CONTINUED)

depreciation as at June 30, 2025 of VND 23,783,166,595 (including VND 20,811,796,801 as at December 31, 2024 and VND 2,971,369,794 for the six-month period of 2025). Based on the audit procedures performed, we were unable to determine the impact of these matters on the interim financial statements for the six-month period of the financial year ending December 31, 2025.

### Auditor's Conclusion

Based on our review, except for the effects of the matters described in the "Basis for Qualified Audit Opinion" paragraph, we have not come across anything that causes us to believe that the accompanying interim financial statements do not present fairly, in all material respects, the interim financial position of Viet My Pharmaceutical and Medical Equipment Production and Trading Joint Stock Company as at 30 June 2025, and the interim results of operations and interim cash flows of the entity for the first 6 months of the fiscal year ended 31 December 2025, in accordance with Vietnamese accounting standards, accounting regimes and legal regulations related to the preparation and presentation of interim financial statements.

### Emphasis of Matters

As of June 30, 2025, the Company's loan at BV Bank is VND 23,126,095,827 and is overdue. As of the issuance date of this report, the above loan is overdue. The extension request period stated in Official Letter No. 05/2024/CV-AMV of the Company was October 2024, and it was approved by BV Bank in Official Letter No. 212/2024/BVbank/CV-QL&THN dated April 9, 2024. However, as of now, the Company has not yet fully repaid the aforementioned principal amount and is continuing to work with the Bank to request an extension (note V.17).

Ha Noi, 28 August, 2025

**NHAN TAM VIET AUDITING COMPANY LIMITED**

**Deputy General Director**



**Nguyen Van Tan**

Auditor's Certificate No. : 5348-2025-124-1

**AMERICAN VIETNAMESE BIOTECH INC**

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City, Vietnam.

**INTERIM FINANCIAL STATEMENTS**

The first 6 months of the fiscal year ending December 31, 2025

**BALANCE SHEET**

As of June 30, 2025

Unit: VND

ASSET	Cod e	Explan a tion	Ending Balance	Beginning Balance
<b>A - SHORT-TERM ASSETS</b>	<b>100</b>		<b>73,167,326,736</b>	<b>181,924,053,900</b>
<b>I. Cash and cash equivalents</b>	<b>110</b>	<b>V.1</b>	<b>3,733,061,864</b>	<b>2,123,348,100</b>
1. Cash	111		3,733,061,864	2,123,348,100
2. Cash equivalents	112		-	-
<b>II. Short-term financial investment</b>	<b>120</b>		<b>-</b>	<b>-</b>
1. Trading securities	121		-	-
2. Provision for impairment of trading securities	122		-	-
3. Held to maturity investment	123		-	-
<b>III. Short-term receivables</b>	<b>130</b>		<b>54,610,994,919</b>	<b>169,243,010,523</b>
1. Short-term trade receivables	131	V.2	6,063,896,543	153,370,344,475
2. Short-term vendor advance	132	V.3	4,001,542,611	9,524,350,514
3. Short-term internal receivables	133		-	-
4. Receivable according to construction contract progress plan	134		-	-
5. Short-term loan receivable	135	V.4	-	500,000,000
6. Other short-term receivables	136	V.5a	44,804,880,893	6,107,640,662
7. Provision for doubtful short-term receivables	137	V.6	(259,325,128)	(259,325,128)
8. Assets missing pending resolution	139		-	-
<b>IV. Inventory</b>	<b>140</b>		<b>14,622,115,770</b>	<b>10,357,695,277</b>
1. Inventory	141	V.7	14,622,115,770	10,357,695,277
2. Provision for inventory write-down	149		-	-
<b>V. Other short-term assets</b>	<b>150</b>		<b>201,154,183</b>	<b>200,000,000</b>
1. Short-term prepaid expenses	151		-	-
2. Deductible value added tax	152		201,154,183	-
3. Taxes and other amounts receivable from the State	153	V.14	-	200,000,000
4. Government bond repurchase transaction	154		-	-
5. Other short-term assets	155		-	-



**AMERICAN VIETNAMESE BIOTECH INC**

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City, Vietnam.

**INTERIM FINANCIAL STATEMENTS**

The first 6 months of the fiscal year ending December 31, 2025

**Interim Balance Sheet (Cont.)**

ASSET	Cod e	Explanat ion	Ending Balance	Beginning Balance
<b>B - LONG-TERM ASSETS</b>	<b>200</b>		<b>1,584,213,465,440</b>	<b>1,485,939,099,062</b>
<b>I. Long-term receivables</b>	<b>210</b>		<b>149,227,000,000</b>	-
1. Long-term receivables from customers	211		-	-
2. Long-term prepayment to seller	212		-	-
3. Working capital in affiliated units	213		-	-
4. Long-term internal receivables	214		-	-
5. Long-term loan receivable	215		-	-
6. Other long-term receivables	216	V.5b	149,227,000,000	-
7. Provision for doubtful long-term receivables	219		-	-
<b>II. Fixed assets</b>	<b>220</b>		<b>64,184,728,105</b>	<b>65,432,066,344</b>
1. Tangible fixed assets	221	V.9	28,402,998,713	26,678,967,158
<i>Original price</i>	222		53,711,890,809	50,034,090,809
<i>Accumulated depreciation</i>	223		(25,308,892,096)	(23,355,123,651)
2. Financial lease fixed assets	224		-	-
<i>Original price</i>	225		-	-
<i>Accumulated depreciation</i>	226		-	-
3. Intangible fixed assets	227	V.10	35,781,729,392	38,753,099,186
<i>Original price</i>	228		59,564,895,987	59,564,895,987
<i>Accumulated depreciation</i>	229		(23,783,166,595)	(20,811,796,801)
<b>III. Investment real estate</b>	<b>230</b>		-	-
<i>Original price</i>	231		-	-
<i>Accumulated depreciation</i>	232		-	-
<b>IV. Long-term unfinished assets</b>	<b>240</b>	<b>V.11</b>	<b>20,691,865,470</b>	<b>20,691,002,908</b>
1. Long-term unfinished production and business costs	241		-	-
2. Cost of unfinished basic construction	242		20,691,865,470	20,691,002,908
<b>V. Long-term financial investment</b>	<b>250</b>	<b>V.12</b>	<b>1,349,960,573,983</b>	<b>1,399,802,674,180</b>
1. Investment in subsidiaries	251	V12 a	1,254,740,000,000	1,284,140,000,000
2. Investment in joint ventures and associates	252	V12 b	153,300,000,000	153,300,000,000
3. Investing in other entities	253		-	-
4. Long-term financial investment reserve	254		(58,079,426,017)	(37,637,325,820)
5. Held to maturity investment	255		-	-
<b>VI. Other long-term assets</b>	<b>260</b>		<b>149,297,882</b>	<b>13,355,630</b>
1. Long-term prepaid expenses	261	V.8	149,297,882	13,355,630
2. Deferred income tax assets	262		-	-
3. Long-term replacement equipment, supplies and spare parts	263		-	-
4. Other long-term assets	268		-	-
<b>TOTAL ASSET</b>	<b>270</b>		<b>1,657,380,792,176</b>	<b>1,667,863,152,962</b>

**AMERICAN VIETNAMESE BIOTECH INC**

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City, Vietnam.

**INTERIM FINANCIAL STATEMENTS**

The first 6 months of the fiscal year ending December 31, 2025

**Interim Balance Sheet (Cont.)**

CAPITAL SOURCE	Code	Explanation	Ending Balance	Beginning Balance
<b>C - LIABILITIES PAYABLE</b>	<b>300</b>		<b>122,871,221,884</b>	<b>122,958,438,171</b>
<b>I. Short-term debt</b>	<b>310</b>		<b>122,871,221,884</b>	<b>122,958,438,171</b>
1. Short-term trade payables	311	V.13	642,964,468	1,149,011,676
2. Short-term advance payment buyer	312		-	-
3. Taxes and other payments to the State	313	V.14	11,928,161	898,719,173
4. Payable to workers	314		1,321,360,916	593,880,249
5. Short-term payable expenses	315	V.15	21,732,252,612	19,760,461,246
6. Short-term internal payables	316		-	-
7. Payable according to construction contract progress schedule	317		-	-
8. Short-term unearned revenue	318		-	-
9. Other short-term payables	319	V.16	76,036,619,900	75,931,270,000
10. Short-term loans and finance leases	320	V.17	23,126,095,827	24,625,095,827
11. Provision for short-term payables	321		-	-
12. Bonus and welfare fund	322		-	-
13. Price stabilization fund	323		-	-
14. Government bond repurchase transaction	324		-	-
<b>II. Long-term debt</b>	<b>330</b>		-	-
1. Long-term trade payables	331		-	-
2. Long term prepayment buyer	332		-	-
3. Long-term payable expenses	333		-	-
4. Internal payable on working capital	334		-	-
5. Long-term internal payables	335		-	-
6. Long-term unrealized revenue	336		-	-
7. Other long-term payables	337		-	-
8. Long-term loans and financial leases	338		-	-
9. Convertible bonds	339		-	-
10. Preferred stock	340		-	-
11. Deferred income tax payable	341		-	-
12. Long-term payables provision	342		-	-
13. Science and Technology Development Fund	343		-	-



**AMERICAN VIETNAMESE BIOTECH INC**

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City, Vietnam.


**INTERIM FINANCIAL STATEMENTS**

The first 6 months of the fiscal year ending December 31, 2025

**Interim Balance Sheet (Cont.)**

CAPITAL SOURCE	Cod e	Explanat ion	Ending Balance	Beginning Balance
<b>D - OWNER'S EQUITY</b>	<b>400</b>		<b>1,534,509,570,292</b>	<b>1,544,904,714,791</b>
<b>I. Equity</b>	<b>410</b>	<b>V.18</b>	<b>1,534,509,570,292</b>	<b>1,544,904,714,791</b>
1. Owner's equity	411		1,311,056,500,000	1,311,056,500,000
- Common shares with voting rights	411a		1,311,056,500,000	1,311,056,500,000
- Preferred stock	411b		-	-
2. Capital surplus	412		(395,300,000)	(395,300,000)
3. Bond conversion option	413		-	-
4. Other owners' equity	414		-	-
5. Treasury stock	415		-	-
6. Asset revaluation difference	416		-	-
7. Exchange rate difference	417		-	-
8. Development investment fund	418		-	-
9. Enterprise Reorganization Support Fund	419		-	-
10. Other equity funds	420		-	-
11. Undistributed profit after tax	421		223,848,370,292	234,243,514,791
- Undistributed profit after tax accumulated to the end of the period	421a		234,243,514,791	246,895,237,887
- Undistributed profit this period	421b		(10,395,144,499)	(12,651,723,096)
12. Source of capital for basic construction investment	422		-	-
<b>II. Other funding sources and funds</b>	<b>430</b>		-	-
1. Funding sources	431		-	-
2. Funds for forming fixed assets	432		-	-
<b>TOTAL CAPITAL</b>	<b>440</b>		<b>1,657,380,792,176</b>	<b>1,667,863,152,962</b>

Prepared by

  
 Nguyen Thu Huyen

Chief Accountant

  
 Dang Thi Thanh Tuyen

Prepared on 28 August, 2025

Director


  
 Dang Nhi Nuong

**AMERICAN VIETNAMESE BIOTECH INC**

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City, Vietnam.

**INTERIM FINANCIAL STATEMENTS**

The first 6 months of the fiscal year ending December 31, 2025

**INTERIM INCOME STATEMENT**

The first 6 months of the fiscal year ending December 31, 2025


Unit: VND

INDICATORS	Code	Explanation	Accumulated from the beginning of the year to the end of this period	
			Current period	Previous period
1. Sales and service revenue	01	VI.1	6,427,336,856	33,117,279,215
2. Revenue deductions	02		-	-
3. Net revenue from sales and services	10		6,427,336,856	33,117,279,215
4. Cost of goods sold	11	VI.2	7,366,727,194	32,299,544,827
5. Gross profit from sales and service provision	20		(939,390,338)	817,734,388
6. Financial revenue	21	VI.3	17,009,703,732	5,000,186,282
7. Financial costs	22	VI.4	22,735,891,563	16,989,674,459
Including: interest expense.	23		2,293,791,366	3,034,589,990
8. Cost of sales	25	VI.5	135,413,326	150,550,707
9. Business management costs	26	VI.6	3,691,974,670	1,812,274,361
10. Net operating profit	30		(10,492,966,165)	(13,134,578,857)
11. Other income	31	VI.7	140,217,607	-
12. Other costs	32	VI.8	42,395,941	32,940,246
13. Other profits	40		97,821,666	(32,940,246)
14. Total accounting profit before tax	50		(10,395,144,499)	(13,167,519,103)
15. Current corporate income tax expense	51	VI.9	-	-
16. Deferred corporate income tax expense	52		-	-
17. Profit after corporate income tax	60		(10,395,144,499)	(13,167,519,103)

Prepared by

  
 Nguyen Thu Huyen

Chief Accountant

  
 Dang Thi Thanh Tuyen

Prepared on 28 August, 2025

Director



Dang Nhi Nuong



**AMERICAN VIETNAMESE BIOTECH INC**

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City, Vietnam.

**INTERIM FINANCIAL STATEMENTS**

The first 6 months of the fiscal year ending December 31, 2025

**INTERIM CASH FLOW STATEMENT****(By indirect method)****The first 6 months of the fiscal year ending December 31, 2025**

Unit: VND

INDICATORS	Co de	Explan ation	Accumulated from the beginning of the year to the end of this period	
			Current period	Previous period
<b>I. Cash flow from operating activities</b>				
1. Profit before tax	01		(10,395,144,499)	(13,167,519,103)
2. Adjustments for the following items:				
- Depreciation of fixed assets and investment real estate	02		5,277,338,239	5,023,460,818
- Provisions	03		20,442,100,197	14,126,324,313
- Exchange rate gains and losses due to revaluation foreign currency monetary items	04		-	-
- Profit and loss from investment activities	05		(17,149,703,732)	(5,000,186,282)
- Interest expense	06		2,293,791,366	3,034,589,990
- Other adjustments	07		-	-
3. Profit from operations before changes in working capital	08		468,381,571	4,016,669,736
- Increase, decrease receivables	09		148,739,998,859	13,888,126,529
- Increase, decrease inventory	10		(4,264,420,493)	19,390,170,174
- Increase, decrease payables	11		(882,007,653)	(5,254,130,495)
- Increase, decrease prepaid expenses	12		(135,942,252)	29,494,656
- Increase, decrease trading securities	13		-	-
- Interest paid	14		-	(23,631,642)
- Corporate income tax paid	15		-	-
- Other income from operating activities	16		-	-
- Other expenses for business activities	17		-	-
<b>Net cash flow from operating activities</b>	<b>20</b>		<b>143,926,010,032</b>	<b>32,046,698,958</b>
<b>II. Cash flow from investing activities</b>				
1. Money spent on purchasing and constructing fixed assets and other long-term assets	21		-	-
2. Proceeds from liquidation and sale of fixed assets and other long-term assets	22		-	-
3. Money spent on lending, buying debt instruments other units	23		-	(10,000,000,000)
4. Proceeds from loan recovery, resale of debt instruments other units	24		500,000,000	5,000,000,000
5. Money spent on investment in other entities	25		(204,227,000,000)	(35,263,500,000)
6. Proceeds from capital investment in other entities	26		40,900,000,000	-
7. Interest income, dividends and profits	27		22,009,703,732	5,000,186,282
<b>Net cash flow from investing activities</b>	<b>30</b>		<b>(140,817,296,268)</b>	<b>(35,263,313,718)</b>

**AMERICAN VIETNAMESE BIOTECH INC**

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City, Vietnam.


**INTERIM FINANCIAL STATEMENTS**

The first 6 months of the fiscal year ending December 31, 2025


**Interim cash flow statement (continued)**

INDICATORS	Co de	Explan ation	Accumulated from the beginning of the year to the end of this period	
			Current period	Previous period
III. Cash flow from financing activities				
1. Proceeds from issuing shares, receiving capital contributions owner	31		-	-
2. Money returned to owners, buyback issued company shares	32		-	-
3. Proceeds from borrowing	33		-	-
4. Loan principal repayment	34		(1,499,000,000)	(2,153,437,823)
5. Lease principal repayment	35		-	-
6. Dividends, profits paid to owners	36		-	-
Net cash flow from financing activities	40		(1,499,000,000)	(2,153,437,823)
Net cash flow during the period	50		1,609,713,764	(5,370,052,583)
Cash and cash equivalents at the beginning of the year	60	V.1	2,123,348,100	6,404,911,296
Impact of Foreign Exchange Rate Fluctuations on Currency Translation	61		-	-
Cash and cash equivalents at the end of the period	70	V.1	3,733,061,864	1,034,858,713

Prepared by

  
 Nguyen Thu Huyen

Chief Accountant

  
 Dang Thi Thanh Tuyen

Prepared on 28 August, 2025

Director





## AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City  
INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2025

Notes to the Interim Financial Statements (next)

### NOTES TO INTERIM FINANCIAL STATEMENTS

First 6 months of the fiscal year ending December 31, 2025

#### I. OPERATION FEATURES

1. **Form of capital ownership** : Joint Stock Company
2. **Business Field** : Medical equipment and medical testing chemicals
3. **Company Overview**

American VietNameese Biotech INC was established under Business Registration Certificate No.3800237998 First issued by the Department of Planning and Investment of Ho Chi Minh City on August 26, 2002. During its operation, the Company has changed its business registration certificate 24 times. The 24rd change in the business registration certificate of a joint stock company was issued on August 17, 2025.

*Charter capital according to the 24rd Business Registration Certificate: VND 1,311,056,500,000*

*Actual contributed capital as of June 30, 2025: VND 1,311,056,500,000*

#### **Headquarters:**

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, Ho Chi Minh City, Vietnam.

Phone: 0651.3.889034

Fax: 0651.3.889032

Tax code: 3 8 0 0 2 3 7 9 9 8

#### 4. **Business sector** :

- Retail of medicines, medical equipment, cosmetics and hygiene products in specialized stores (Details: pharmaceutical business, buying and selling medical equipment, medical testing tools and chemicals);
  - Manufacture of medical, dental, orthopedic and rehabilitation equipment and instruments (Details: Manufacturing medical testing equipment);
  - Production of drugs, pharmaceutical chemicals and medicinal materials (Details: Production and trading of vaccines and medical biological products);
  - Production of cosmetics, soaps, detergents, polishes and cleaning products; Agents, brokers, auctioneers (Details: Agents for consignment of goods, production of plastic products);
  - Real estate business, land use rights owned, used or rented (Details: Real estate business);
  - Water exploitation, treatment and supply; Drainage and wastewater treatment; Scrap recycling; Pollution treatment and other waste management activities;
  - Other professional, scientific and technological activities not elsewhere classified (Details: Technology transfer);
  - Other business lines specifically specified in the Business Registration Certificate./.
- Main business activities: Trading in medical equipment and medical testing chemicals.

**AMERICAN VIETNAMESE BIOTECH INC**

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

**INTERIM FINANCIAL REPORT**

First 6 months of the fiscal year ending December 31, 2025

Notes to the Interim Financial Statements (next)

**5. Normal production and business cycle**

Normal business production cyclecompany no more than 12 months.

**6. Statement on comparability of information in financial statements**

The interim financial statements for the first 6 months of the fiscal year ending December 31, 2025 are fully consistent and comparable with the interim financial statements for the first 6 months of the fiscal year ending December 31, 2024 and the financial statements for the fiscal year ending December 31, 2024.

**7. Staff**

At the end of the accounting period, the Company had 35 employees working (the number at the beginning of the year was 30 employees).

**8. Business structure:****a, Subsidiary**

Company Name	Head office Totalress	Ownersh ip ratio	Voting ratio	Main business lines
Viet My Hospital Investment Joint Stock Company	No. 307 Nguyen Du extended street, Nong Trang ward, Viet Tri city, Phu Tho province, Vietnam	83.33%	83.33%	Wholesale of pharmaceuticals and medical instruments, wholesale of medical machinery and equipment Manufacture of medicines,
Ha Long Kyoto Technology Development Joint Stock Company	Lot A15, Nam Son Industrial Park, Nam Son Commune, Ba Che District, Quang Ninh Province	99.00%	99.00%	pharmaceutical chemicals and pharmaceutical materials. Manufacture of ovens, furnaces and kilns
Kyoto Bai Chay Clinic Joint Stock Company	No. 4, Group 4, Bai Chay Ward, Quang Ninh Province, Vietnam	98,00%	98,00%	General, specialist and dental clinics
Song Hau New Technology Application Research Joint Stock Company	Song Hau Industrial Park, Phase 1, Chau Thanh Commune, Can Tho City, Vietnam	98,00%	98,00%	General, specialist and dental clinics
Ha Dong Clinic Joint Stock Company	3rd Floor, No. 1 Phuc Thinh, Cau Buou, Kien Hung Ward, Hanoi City	98,00%	98,00%	General, specialist and dental clinics
Hoa Binh Clinic Joint Stock Company	1st Floor, No. 83 Cu Chinh Lan Street, Group 13, Hoa Binh Ward, Phu Tho Province, Vietnam	98,00%	98,00%	General, specialist and dental clinics
Viet Tri Clinic Joint Stock Company	No. 307 Nguyen Du Extended Street, Nong Trang Ward, Phu Tho Province, Vietnam	98,00%	98,00%	General, specialist and dental clinics
Gia Lam High-Tech Clinic Joint Stock Company	No. 18, Lot BT5, Phap Van – Tu Hiep Urban Area, Yen So Ward, Hanoi City, Vietnam	98,00%	98,00%	General, specialist and dental clinics
Medicare Can Tho Clinic Joint Stock Company	No. 408 Nguyen Van Cu Street, An Binh Ward, Can Tho City, Vietnam	98,00%	98,00%	General, specialist and dental clinics
Medicare Hau Giang Clinic Joint Stock Company	No. 16, 1st Floor, Street No. 14, Zone 4, Vi Thanh Ward, Can Tho City, Vietnam	98,00%	98,00%	General, specialist and dental clinics



**AMERICAN VIETNAMESE BIOTECH INC**

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

**INTERIM FINANCIAL REPORT**

First 6 months of the fiscal year ending December 31, 2025

**Notes to the Interim Financial Statements (next)**

Medicare Soc Trang Clinic Joint Stock Company	1st Floor, No. 438 Le Duan Street, Hamlet 4, Phu Loi Ward, Can Tho City, Vietnam	98,00%	98,00%	General, specialist and dental clinics
Medicare Nga Bay Clinic Joint Stock Company	No. 222, 30/4 Street, Zone 5, Nga Bay Ward, Can Tho City, Vietnam	98,00%	98,00%	General, specialist and dental clinics
Leopard Solutions Joint Stock Company	No. 34, Street 79, Dinh Hamlet, Cu Chi Commune, Ho Chi Minh City, Vietnam	75,00%	75,00%	Computer programming
Vietnam National Software Production Joint Stock Company (*)	No. 36, BT5, Phap Van – Tu Hiep Urban Area, Hoang Mai Ward, Hanoi City	98,00%	98,00%	Computer programming

(\*)Resolution of the Board of Directors No. 2502.01/2025/NQ-HĐQT dated February 25, 2025 on divestment of investment capital at Vietnam National Software Production Joint Stock Company. As of the issuance date of this report, the Company has fully divested its capital in this subsidiary.

The other subsidiaries are operating under normal business conditions.

***b, Indirectly owned subsidiaries:***

Company name	Head office Totalress	Owners hip ratio	Voting ratio	Main business lines
Famicare Thu Duc Joint stock Company	No. 28 Hien Vuong Street, Tang Nhon Phu Ward, Ho Chi Minh City, Vietnam	96,04%	96,04%	General, specialist and dental clinics
Medicare Nha Be Clinic Joint Stock Company	1st Floor, No. 178 Nguyen Thai Son Street, Hanh Thong Ward, Ho Chi Minh City, Vietnam	96,04%	96,04%	General, specialist and dental clinics
Famicare Vinh Yen Joint Stock Company	2nd Floor, No. 79 Ba Trieu Street, Vinh Phuc Ward, Phu Tho Province, Vietnam	88,2%	88,2%	General, specialist and dental clinics

The other subsidiaries are operating under normal business conditions.

***c, Associate company:***

Company name	Head office Totalress	Owners hip ratio	Voting ratio	Main business lines
Medicare Huu Nghi Clinic Joint Stock Company	No. 179 Giai Phong Street, Bach Mai Ward, Hanoi City, Vietnam	49%	49%	General, specialist and dental clinics
Golab Ninh Binh Testing Center Joint Stock Company	1st Floor, No. 140 Tue Tinh Street, Hoa Lu Ward, Ninh Binh City, Vietnam	35%	35%	General, specialist and dental clinics
Golab Phap Van Testing Center Joint Stock Company	1st Floor, Lot BT5, No. 18 Phap Van – Tu Hiep New Urban Area, Yen So Ward, Hanoi City, Vietnam	35%	35%	General, specialist and dental clinics
Famicare Phap Van Joint Stock Company	1st Floor, Lot BT5, No. 17 Phap Van – Tu Hiep New Urban Area, Yen So Ward, Hanoi City, Vietnam	35%	35%	General, specialist and dental clinics
Golab Go Vap Testing	1st Floor, No. 178 Nguyen Thai Son	35%	35%	General, specialist and

**AMERICAN VIETNAMESE BIOTECH INC**

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

**INTERIM FINANCIAL REPORT**

First 6 months of the fiscal year ending December 31, 2025

**Notes to the Interim Financial Statements (next)**

Center Joint Stock Company	Street, Hanh Thong Ward, Ho Chi Minh City, Vietnam			dental clinics
Nghe An Clinic Joint Stock Company	1st Floor, No. 68 Ho Tong Thoc Street, Block 13, Vinh Phu Ward, Nghe An Province, Vietnam	35%	35%	General, specialist and dental clinics
Ba Dinh Clinic Joint Stock Company	No. 37A Doc Phu San, De La Thanh Street, Lang Ward, Hanoi City, Vietnam	35%	35%	General, specialist and dental clinics
Golab Bac Lieu Testing Center Joint Stock Company	Ground Floor, No. 210 Ba Trieu Street, Bac Lieu Ward, Ca Mau Province, Vietnam	35%	35%	General, specialist and dental clinics
Golab Binh Duong Testing Center Joint Stock Company	No. 634 Binh Duong Boulevard, Zone 5, Phu Loi Ward, Ho Chi Minh City, Vietnam	35%	35%	General, specialist and dental clinics
Famicare Tuyen Quang Joint Stock Company	2nd Floor, No. 23 Hoa Lu Street, Group 01, Minh Xuan Ward, Tuyen Quang Province, Vietnam	35%	35%	General, specialist and dental clinics
Golab Vung Tau Testing Center Joint Stock Company	No. 745 Vo Van Kiet Street, Tam Long Ward, Ho Chi Minh City, Vietnam	49%	49%	General, specialist and dental clinics
Golab Ha Giang Testing Center Joint Stock Company	1st Floor, No. 75 Nguyen Thai Hoc Street, Group 22, Ha Giang 2 Ward, Tuyen Quang Province, Vietnam	49%	49%	General, specialist and dental clinics
Golab Tien Giang Testing Center Joint Stock Company	No. 368A, Phuoc Hoa Hamlet, Trung An Ward, Dong Thap Province, Vietnam	35%	35%	General, specialist and dental clinics

**d. Dependent accounting units:**

Name	Address	Main Activities
Representative Office of Viet My Pharmaceutical and Medical Equipment Production and Trading Joint Stock Company	A30-A31, D1 Street, Tan Hai Minh Residential Area, KP1, Thu Duc Ward, Ho Chi Minh City	Trading of pharmaceuticals; purchase and sale of medical equipment, instruments, and laboratory chemicals (Normal operations)
Branch of Viet My Pharmaceutical and Medical Equipment Production and Trading Joint Stock Company	2nd Floor, Lot No. 36, BT5 Phap Van – Tu Hiep New Urban Area, Yen So Ward, Hanoi City, Vietnam	Trading of pharmaceuticals; purchase and sale of medical equipment, instruments, and laboratory chemicals (Normal operations)

**II. FISCAL YEAR, CURRENCY USED IN ACCOUNTING****1. Fiscal year**

The Company's fiscal year begins on January 1 and ends on December 31 of each year.

**2. Currency used in accounting**

The currency used in accounting is Vietnamese Dong (VND) because revenue and expenditure are mainly made in VND.



## **AMERICAN VIETNAMESE BIOTECH INC**

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

### **INTERIM FINANCIAL REPORT**

First 6 months of the fiscal year ending December 31, 2025

**Notes to the Interim Financial Statements (next)**

### **III. ACCOUNTING STANDARDS AND REGIMES APPLIED**

#### **1. Applicable accounting standards**

The Company applies accounting standards, Vietnamese Enterprise Accounting Regime issued under Circular No. 200/2014/TT-BTC dated December 22, 2014, Circular No. 53/2016/TT-BTC dated March 21, 2016 amending and supplementing a number of articles of Circular No. 200/2014/TT-BTC and circulars guiding the implementation of accounting standards of the Ministry of Finance in preparing and presenting Financial Statements.

#### **2. Statement on compliance with accounting standards and accounting regimes**

The Board of Directors ensures that it has complied with the requirements of accounting standards, the Vietnamese Enterprise Accounting Regime issued under Circular No. 200/2014/TT-BTC dated December 22, 2014, Circular No. 53/2016/TT-BTC dated March 21, 2016 amending and supplementing a number of articles of Circular No. 200/2014/TT-BTC as well as circulars guiding the implementation of accounting standards of the Ministry of Finance in preparing Financial Statements.

### **IV. ACCOUNTING STANDARDS AND REGIMES APPLIED**

#### **1. Basis for preparing financial statements**

Financial statements are prepared on the accrual basis of accounting (except for information relating to cash flows).

Users of these interim financial statements should read them together with the interim consolidated financial statements of the Company and its subsidiaries ("the Group") for the six-month period ended 31 December 2025 in order to obtain full information on the financial position, results of operations and cash flows of the Group as a whole.

#### **2. Cash and cash equivalents**

Cash includes cash on hand, demand deposits, monetary gold used for value storage purposes, excluding gold classified as inventories used as raw materials for the production of products or goods for sale.

Cash equivalents are short-term investments with a maturity of no more than three months from the date of purchase, which are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value.

#### **3. Financial investments**

##### ***Loans***

Loans are measured at cost less allowance for doubtful debts. Allowance for doubtful debts on loans is made based on the expected level of loss that may occur.

##### ***Investments in subsidiaries, joint ventures and associates***

##### ***Subsidiary***

A subsidiary is an enterprise controlled by the Enterprise. Control is achieved when the Enterprise has the power to govern the financial and operating policies of an investee enterprise so as to obtain benefits from its activities.

Investments in subsidiaries and associates are initially recorded at cost, including the purchase price or capital contribution plus costs directly related to the investment. In case of investment in non-monetary assets, the cost of the investment is recorded at the fair value of the non-monetary assets at the time of acquisition.

Dividends and profits from periods prior to the investment being purchased are recorded as a reduction in the value of the investment itself. Dividends and profits from periods subsequent to the investment



## AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

### INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2025

Notes to the Interim Financial Statements (next)

being purchased are recorded as revenue. Dividends received in shares are only tracked by the number of shares increased, not the value of the shares received/recorded at par value.

Provision for losses on investments in subsidiaries and associates is made when the subsidiary or associate suffers a loss, with the provision equal to the difference between the actual capital contributions of the parties in the subsidiary, joint venture or associate and the actual equity multiplied by the ratio of the Enterprise's capital contribution to the total actual capital contributions of the parties in the subsidiary or associate. If the subsidiary or associate is the subject of the Consolidated Financial Statement, the basis for determining the provision for losses is the Consolidated Financial Statement.

Increase or decrease in the provision for investment losses in subsidiaries and associates that must be set up at the end of the fiscal year is recorded in financial expenses.

#### *Investments in equity instruments of other entities*

Investments in equity instruments of other entities include investments in equity instruments but the Enterprise does not have control, joint control or significant influence over the investee.

Investments in equity instruments of other entities are initially recorded at cost, including the purchase price or capital contribution plus direct costs related to the investment. Dividends and profits from periods prior to the investment being purchased are recorded as a reduction in the value of the investment itself. Dividends and profits from periods subsequent to the investment being purchased are recorded as revenue. Dividends received in shares are only tracked by the number of Totalitional shares, not recording the value of shares received/recorded at par value (except for state-owned enterprises in accordance with current regulations of law).

Provision for losses on investments in equity instruments of other entities is made as follows:

- For investments in listed shares or for which the fair value of the investment is reliably determined, the provision is based on the market value of the shares.
- For investments whose fair value cannot be determined at the reporting date, provisions are made based on the loss of the investee with the provision equal to the difference between the actual capital contribution of the parties at other entities and the actual equity multiplied by the capital contribution ratio of the Enterprise compared to the total actual capital contribution of the parties at other entities.

Increases and decreases in the provision for investment losses in equity instruments of other entities that need to be set up at the end of the fiscal year are recorded in financial expenses.

#### 4. **Accounts Receivable**

Accounts receivable are stated at carrying amount less allowance for doubtful debts.

The classification of receivables as trade receivables and other receivables is carried out according to the following principles:

- Trade receivables reflect commercial receivables arising from purchase-sale transactions between the company and buyers who are independent entities, including receivables from export sales entrusted to other entities.
- Other receivables reflect non-commercial receivables not related to purchase and sale transactions.

Provision for doubtful debts is made for each doubtful debt based on the age of overdue debts or the expected level of loss that may occur, specifically as follows:

- For overdue receivables:
  - 30% of the value for overdue receivables from 6 months to less than 1 year.
  - 50% of the value for overdue receivables from 1 year to less than 2 years.
  - 70% of the value for receivables overdue from 2 years to less than 3 years.
  - 100% of the value for receivables 3 years or more old.



## AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

### INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2025

Notes to the Interim Financial Statements (next)

- For receivables that are not overdue but are unlikely to be recovered: establish provisions based on expected loss level.

#### 5. Inventory

Inventories are goods and are stated at the lower of cost and net realizable value. The cost of inventories is determined including the cost of purchase and other directly relevant costs incurred in bringing the inventories to their present location and condition.

Net realizable value is the estimated selling price of inventories in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale. Inventories are valued at cost using the weighted average method and accounted for using the perpetual inventory method.

Provision for inventory devaluation is established for each inventory item whose original cost is greater than its net realizable value. For unfinished services, provision for devaluation is calculated for each type of service with a separate price. Increases and decreases in the balance of provision for devaluation of inventory required to be established at the end of the fiscal year are recorded in cost of goods sold.

#### 6. Prepaid expenses

Prepaid expenses include actual expenses that have been incurred but are related to the results of production and business activities of many accounting periods. The company's prepaid expenses are the cost of tools and equipment.

##### *Tools, instruments*

Tools and equipment put into use are allocated to expenses using the straight-line method with an allocation period of no more than 03 years.

#### 7. Tangible fixed assets

Tangible fixed assets are stated at cost less accumulated depreciation. The cost of tangible fixed assets includes all costs incurred by the company to acquire the fixed assets up to the time the assets are ready for use. Expenses incurred after initial recognition are only recorded as an increase in the cost of fixed assets if it is certain that these costs will increase future economic benefits from the use of the assets. Expenses incurred that do not satisfy the above conditions are recorded as production and business expenses in the period.

When tangible fixed assets are sold or disposed of, their cost and accumulated depreciation are eliminated from the accounts and any gain or loss resulting from their disposal is recognized as income or expense in the year.

Tangible fixed assets are depreciated using the straight-line method over their estimated useful lives. The depreciation years for various types of Tangible Fixed Assets are as follows:

<u>Type of fixed asset</u>	<u>No. 5</u>
Machinery and equipment	06-10

#### 8. Intangible fixed assets

Intangible fixed assets are stated at cost less accumulated depreciation.

The original cost of intangible fixed assets includes all costs that Company must be spent to acquire fixed assets up to the time the asset is ready for use. Expenditures relating to intangible fixed assets incurred after initial recognition are recognised as expenses in the period in which they are incurred, unless they are associated with a specific intangible fixed asset and result in an increase in the economic benefits derived from the asset.

## **AMERICAN VIETNAMESE BIOTECH INC**

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

### **INTERIM FINANCIAL REPORT**

First 6 months of the fiscal year ending December 31, 2025

**Notes to the Interim Financial Statements (next)**

Intangible fixed assets of Company include:

#### ***Software program***

Costs relating to computer software programs that are not part of the related hardware are capitalized. The cost of computer software is the total cost incurred by the Company up to the date the software is put into use. Computer software is amortized on a straight-line basis over 10-20 years.

#### **9. Cost of unfinished basic construction**

Construction in progress reflects directly related costs (including interest expenses related to the Company's accounting policies) to assets under construction, machinery and equipment being installed for production, leasing and management purposes as well as costs related to repairs of fixed assets in progress. These assets are recorded at original cost and not depreciated.

#### **10. Accounts Payable and Accrued Expenses**

Liabilities and accruals are recognized for amounts to be paid in the future for goods and services received. Accruals are recognized based on reasonable estimates of the amounts to be paid.

The classification of payables as trade payables, accrued expenses, internal payables and other payables is carried out according to the following principles:

- Trade payables reflect commercial payables arising from transactions of purchasing goods, services, assets and the seller is an independent entity of the company, including payables when importing through consignees.
- Payable expenses reflect amounts payable for goods and services received from sellers or provided to buyers but not yet paid due to lack of invoices or insufficient accounting records and documents, and amounts payable to employees for leave wages, production and business expenses that must be accrued in advance.
- Other payables reflect non-commercial payables not related to the purchase, sale or provision of goods and services.

#### **11. Equity**

##### ***Owner's equity***

Owner's equity is recorded according to the actual capital contributed by shareholders.

##### ***Capital surplus***

Share capital surplus is recorded as the difference between the issue price and the par value of shares when first issued, Totalitional issued or the difference between the reissue price and the book value of treasury shares. Direct costs related to the Totalitional issuance of shares and reissuance of treasury shares are recorded as a decrease in share capital surplus.

##### ***Other owners' equity***

Other capital is formed by supplementing from business results, revaluation of assets and the remaining value between the fair value of donated, presented, and sponsored assets after deducting taxes payable (if any) related to these assets.

#### **12. Profit distribution**

Profit after corporate income tax is distributed to shareholders after setting aside funds according to the Company's Charter as well as legal regulations and approved by the General Meeting of Shareholders.

The distribution of profits to shareholders takes into account non-cash items in undistributed earnings that may affect cash flows and the ability to pay dividends. Gains from revaluation of assets contributed as capital, gains from revaluation of monetary items, financial instruments and other non-monetary items.



## **AMERICAN VIETNAMESE BIOTECH INC**

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

### **INTERIM FINANCIAL REPORT**

First 6 months of the fiscal year ending December 31, 2025

**Notes to the Interim Financial Statements (next)**

#### ***Other funds***

Funds are set aside and used in accordance with the Company Charter and the Resolution of the Annual Shareholders' Meeting.

Dividends are recognized as liabilities when approved by the General Meeting of Shareholders.

### **13. Revenue and income recognition**

#### ***a) Sales revenue***

Revenue from the sale of goods is recognized when all of the following conditions are simultaneously satisfied:

- The company has transferred to the buyer the significant risks and rewards of ownership of the products or goods.
- The Company no longer holds title to the goods or control over the goods.
- Revenue is determined with relative certainty. When the contract stipulates that the buyer has the right to return the purchased products or goods under specific conditions, revenue is only recognized when those specific conditions no longer exist and the buyer is not entitled to return the products or goods (except in cases where the customer has the right to return the goods in exchange for other goods or services).
- The Company has obtained or will obtain economic benefits associated with the sale transaction.
- Identify the costs associated with a sales transaction

#### ***b) Service revenue***

Revenue from a service transaction is recognised when the outcome of the transaction can be measured reliably. In cases where the service is performed over several periods, revenue is recognised in each period based on the results of the work completed at the end of the accounting period. The outcome of a service transaction is recognised when all of the following conditions are met:

- Revenue is measured reliably. When a contract provides that the buyer has the right to return the services purchased under specific conditions, revenue is recognized only when the specific conditions no longer exist and the buyer has no right to return the services provided.
- It is possible to obtain economic benefits from the transaction of providing that service.
- Determine the portion of work completed as of the end of the fiscal year.
- Identify the costs incurred for the transaction and the costs to complete the transaction to provide that service.

#### ***c) Interest***

Interest is recognized on an accrual basis, determined on the deposit account balance and the actual interest rate for each period.

#### ***d) Dividends and profits distributed***

Dividends and profits distributed are recognized when the company is entitled to receive dividends or profits from capital contributions. Dividends received in shares are only tracked by the number of shares increased, not recorded at par value of shares received.

### **14. Cost of goods sold.**

Cost of goods sold during the year is recorded in accordance with revenue generated during the period and ensures compliance with the principle of prudence.

### **15. Borrowing costs**

Borrowing costs include interest and other costs incurred in connection with borrowing.

## AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

### INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2025

Notes to the Interim Financial Statements (next)

#### 16. Corporate income tax

##### *Current income tax*

Current income tax is the tax that is calculated on taxable income. Taxable income differs from accounting profit due to adjustments for temporary differences between tax and accounting, non-deductible expenses as well as adjustments for non-taxable income and losses carried forward.

#### 17. Financial instruments

##### i. Financial assets

###### *Classification of financial assets*

The Company classifies its financial assets into the following groups: financial assets at fair value through the Statement of Business Performance, investments held to maturity, loans and receivables, and available-for-sale financial assets. The classification of these financial assets depends on the nature and purpose of the financial assets and is determined at the time of initial recognition.

###### *Financial assets are recorded at fair value through the Statement of Business Performance*

Financial assets are classified as measured at fair value through the Statement of Income if they are held for trading or designated as such at fair value through the Statement of Income upon initial recognition.

Financial assets are classified as held for trading securities if:

- Purchased or created primarily for the purpose of resale in the short term;
- The Company intends to hold for the purpose of short-term profit;
- Derivative financial instruments (except for derivative financial instruments that are identified as a financial guarantee contract or a designated and effective hedging instrument).

###### *Held to maturity investments*

Held-to-maturity investments are non-derivative financial assets with fixed or determinable payments and fixed maturity that the Company has the intention and ability to hold to maturity.

###### *Loans and receivables*

Loans and receivables are non-derivative financial assets with fixed or determinable payments and are not listed on an active market.

###### *Financial assets available for sale*

Available-for-sale financial assets are non-derivative financial assets that are designated as available-for-sale or that are not classified as financial assets at fair value through profit or loss, held-to-maturity investments, or loans and receivables.

###### *Initial book value of financial assets*

Financial assets are recognised at the date of acquisition and derecognised at the date of sale. At the time of initial recognition, financial assets are measured at their purchase price/issuance costs plus any other costs directly attributable to the acquisition or issue of the financial asset.

##### ii. Financial liabilities

The Company classifies financial liabilities into groups: financial liabilities recorded at fair value through the Income Statement, financial liabilities determined at amortized cost. The classification of financial liabilities depends on the nature and purpose of the financial liability and is determined at the time of initial recognition.

###### *Financial liabilities are recorded at fair value through the Statement of Income.*

A financial liability is classified as measured at fair value through the Statement of Income if it is held for trading or designated as such at fair value through the Statement of Income upon initial recognition.

Financial liabilities are classified as held for trading securities if:

- Issued or created primarily for the purpose of repurchasing in the short term;
- The Company intends to hold for the purpose of short-term profit;



## **AMERICAN VIETNAMESE BIOTECH INC**

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, TanMy Ward, Ho Chi Minh City

### **INTERIM FINANCIAL REPORT**

First 6 months of the fiscal year ending December 31, 2025

**Notes to the Interim Financial Statements (next)**

- Derivative financial instruments (except for derivative financial instruments that are identified as a financial guarantee contract or a designated and effective hedging instrument).

*Financial liabilities are measured at amortized cost.*

Financial liabilities are measured at amortised cost, which is the amount at which the financial liability is initially recognised minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and minus any reduction (directly or through the use of an allowance account) for impairment or uncollectibility.

The effective interest method is a method of calculating the amortized cost of a financial liability or group of financial liabilities and allocating interest income or expense over the relevant period. The effective interest rate is the rate at which estimated future cash flows that will be paid or received over the expected life of the financial instrument or, if appropriate, shorter, are discounted to the net present carrying amount of the financial liability.

*Initial book value of financial liability*

At initial recognition, financial liabilities are measured at issue price plus any costs directly attributable to the issue of the financial liability.

#### **iii. Equity instruments**

An equity instrument is a contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

#### **18. Related parties**

Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control or common significant influence.

In considering any related party relationship, attention is directed more to the substance of the relationship than to the legal form.

Transactions with related parties during the period are presented in note VII.1.

**AMERICAN VIETNAMESE BIOTECH INC**

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

**INTERIM FINANCIAL REPORT**

First 6 months of the fiscal year ending December 31, 2025

Notes to the Interim Financial Statements (next)

**V. TOTALITIONAL INFORMATION FOR ITEMS PRESENTED IN THE INTERIM BALANCE SHEET****1. Cash and cash equivalents**

	<u>Ending Balance</u>	<u>Beginning Balance</u>
Cash	2,286,097,101	290,950,121
Non-term bank deposits	1,446,964,763	1,832,397,979
<b>Total</b>	<b>3,733,061,864</b>	<b>2,123,348,100</b>

**2. Short-term receivables from customers**

	<u>Ending Balance</u>		<u>Beginning Balance</u>	
	<u>Value</u>	<u>Preventive</u>	<u>Value</u>	<u>Preventive</u>
<i>Receivables from related parties</i>	<i>154,000,000</i>	-	<i>82,715,368,400</i>	-
Medicare Huu Nghi Clinic Joint Stock Company	-	-	244,200,000	-
Golab Phap Van Test Center Joint Stock Company	38,500,000	-	242,000,000	-
Golab Hai Phong Test Center Joint Stock Company	-	-	2,932,070,200	-
Golab Hai Duong Test Center Joint Stock Company	-	-	7,159,494,700	-
Golab Hung Yen Test Center Joint Stock Company	-	-	7,013,194,700	-
Golab Quang Binh Test Center Joint Stock Company	-	-	2,913,210,200	-
Golab Dong Thap Test Center Joint Stock Company	-	-	2,768,270,200	-
Golab Vinh Long Test Center Joint Stock Company	-	-	2,768,270,200	-
Golab An Giang Test Center Joint Stock Company	-	-	2,725,370,200	-
Famicare Kien Giang Joint Stock Company	-	-	4,335,384,500	-
Golab Kien Giang Test Center Joint Stock Company	-	-	6,767,870,200	-
Golab Bac Ninh Test Center Joint Stock Company	-	-	7,128,594,700	-
Golab Vinh Phuc Test Center Joint Stock Company	-	-	7,364,884,500	-
Golab Ninh Binh Test Center Joint Stock Company	38,500,000	-	42,900,000	-
Golab Ha Tinh Test Center Joint Stock Company	-	-	4,385,784,500	-
Famicare Quang Binh Joint Stock Company	-	-	4,315,384,500	-
Golab Bien Hoa Test Center Joint Stock Company	38,500,000	-	4,042,500,000	-
Golab Gia Lai Test Center Joint Stock Company	-	-	2,832,870,200	-
Famicare Vinh Long Joint Stock	-	-	7,075,694,700	-



**AMERICAN VIETNAMESE BIOTECH INC**

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

**INTERIM FINANCIAL REPORT**

First 6 months of the fiscal year ending December 31, 2025

**Notes to the Interim Financial Statements (next)**

	Ending Balance		Beginning Balance	
	Value	Preventive	Value	Preventive
Company				
Golab Tan An Test Center Joint Stock Company	-	-	2,822,420,200	-
Viet My Hospital Investment Joint Stock Company	-	-	2,835,000,000	-
Nghe An Clinic Joint Stock Company	38,500,000	-	-	-
<b>Receivables from other customers</b>	<b>5,909,896,543</b>	<b>(259,325,128)</b>	<b>70,654,976,075</b>	<b>(259,325,128)</b>
Tot Server Technology Joint Stock Company	993,625,600	-	1,993,625,600	-
Hanoi Pediatrics Hospital	1,283,562,700	-	283,939,200	-
Lou Investment Joint Stock Company	-	-	18,302,003,421	-
Can Tho Test and Environmental Center Joint Stock Company	-	-	45,502,587,900	-
Other customers	3,632,708,243	(259,325,128)	4,572,819,954	(259,325,128)
<b>Total</b>	<b>6,063,896,543</b>	<b>(259,325,128)</b>	<b>153,370,344,475</b>	<b>(259,325,128)</b>

**3. Short-term seller advance**

	Ending Balance		Beginning Balance	
	Value	Preventive	Value	Preventive
<b>Prepay to other sellers</b>	<b>4,001,542,611</b>	-	<b>9,524,350,514</b>	-
Japan Kanpeki Joint stock Company	3,084,933,198	-	3,769,563,726	-
Amvi Japan Co.,Ltd	700,208,788	-	700,208,788	-
Nha Trang Medical Hi-Tech Application Joint Stock Company (*)	-	-	5,000,000,000	-
Other suppliers	216,400,625	-	54,578,000	-
<b>Total</b>	<b>4,001,542,611</b>	-	<b>9,524,350,514</b>	-

(\*) These are advances for the purpose of purchasing machinery, software, and medical equipment for production and business activities. However, due to the deadline for providing the machines, the parties have terminated the contract and returned the money. The Company has recovered the entire amount of the advance.

**4. Short-term loans receivable**

This is a capital support provided to Golab Binh Duong Laboratory Center Joint Stock Company, which has been fully recovered as of the date of issuance of this report.

**AMERICAN VIETNAMESE BIOTECH INC**

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

**INTERIM FINANCIAL REPORT**

First 6 months of the fiscal year ending December 31, 2025

Notes to the Interim Financial Statements (next)

**5. Other Receivables****a, Other Short-term Receivables**

	Ending Balance		Beginning Balance	
	Value	Preventive	Value	Preventive
<i>Receivables from related parties</i>	-	-	5,000,000,000	-
Vietnam National Software Production JSC – Dividends and distributed profits receivable	-	-	5,000,000,000	-
<i>Receivables from other organizations and individuals</i>	44,804,880,893	-	1,107,640,662	-
Advance payment	-	-	169,775,746	-
Deposits and collaterals	1,276,880,893	-	937,864,916	-
Phu Tho Provincial General Hospital (*)	43,500,000,000	-	-	-
Other short-term receivables	28,000,000	-	-	-
<b>Total</b>	<b>44,804,880,893</b>	<b>-</b>	<b>6,107,640,662</b>	<b>-</b>

**b, Other Long-term Receivables**

	Ending Balance		Beginning Balance	
	Value	Preventive	Value	Preventive
<i>Receivables from other organizations and individuals</i>	149,227,000,000	-	-	-
Phu Tho Provincial General Hospital (*)	149,227,000,000	-	-	-
<b>Total</b>	<b>149,227,000,000</b>	<b>-</b>	<b>-</b>	<b>-</b>

(\*) Under Contract No. 01/2025/HĐCN/SARA-VIETMY dated February 15, 2025, the Company acquired the capital contribution of Sara Vietnam Joint Stock Company in Phu Tho Provincial General Hospital for the purpose of investing in the construction of the Obstetrics and Pediatrics Center of Phu Tho Provincial General Hospital, with a transfer value of VND 204,227,000,000.

However, pursuant to Resolution of the Board of Directors No. 1604/2025/NQ-BOD dated April 16, 2025, the Company resolved to withdraw its investment in Phu Tho Obstetrics and Pediatrics Hospital ahead of schedule. On April 21, 2025, the Company and the Hospital executed Annex No. 05 to the contract regarding the early withdrawal of capital. Accordingly, the Hospital shall refund the Company's contributed capital in installments from 2025 to 2028. As of the date of issuance of this report, the Hospital has reimbursed the Company VND 17.5 billion.

**6. Bad debt**

	Ending Balance		Beginning Balance	
	Original price	Recoverable value	Original price	Recoverable value
Hau Giang Tuberculosis and Lung Hospital	35,168,802	-	35,168,802	-
Phu Tho Provincial General Hospital	25,420,002	-	25,420,002	-
Gia Rai Town Medical Center	27,496,482	-	27,496,482	-
Central Lung Hospital	171,239,842	-	171,239,842	-
<b>Total</b>	<b>259,325,128</b>	<b>-</b>	<b>259,325,128</b>	<b>-</b>



**AMERICAN VIETNAMESE BIOTECH INC**

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

**INTERIM FINANCIAL REPORT**

First 6 months of the fiscal year ending December 31, 2025

Notes to the Interim Financial Statements (next)

**7. Inventory**

	Ending Balance		Beginning Balance	
	Value	Provision	Value	Provision
Goods	14,622,115,770	-	10,357,695,277	-
<b>Total</b>	<b>14,622,115,770</b>	<b>-</b>	<b>10,357,695,277</b>	<b>-</b>

**8. Long-term prepaid expenses**

	Ending Balance	Beginning Balance
Tools and Supplies	39,846,001	-
Other long-term prepaid expenses	109,451,881	13,355,630
<b>Total</b>	<b>149,297,882</b>	<b>13,355,630</b>

**9. Tangible fixed assets**

	Machinery and equipment	Total
<b>Historical Cost</b>		
Beginning Balance	50,034,090,809	50,034,090,809
Completed capital construction investment	4,030,000,000	4,030,000,000
Disposal of assets	(352,200,000)	(352,200,000)
<b>Ending Balance</b>	<b>53,711,890,809</b>	<b>53,711,890,809</b>
<i>Including:</i>		
Fully depreciated but still in use	7,392,200,000	7,392,200,000
<b>Accumulated depreciation</b>		
Beginning Balance	23,355,123,651	23,355,123,651
Depreciation during the year	2,305,968,445	2,305,968,445
Disposal of assets	(352,200,000)	(352,200,000)
<b>Ending Balance</b>	<b>25,308,892,096</b>	<b>25,308,892,096</b>
<b>Remaining Value</b>		
Beginning Balance	26,678,967,158	26,678,967,158
<b>Ending Balance</b>	<b>28,402,998,713</b>	<b>28,402,998,713</b>

Some tangible fixed assets are machinery and equipment with original cost and residual value of VND 38,916,611,293 and VND 23,015,200,232 is being mortgaged for the loan at Viet Capital Commercial Joint Stock Bank.

**AMERICAN VIETNAMESE BIOTECH INC**

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

**INTERIM FINANCIAL REPORT**

First 6 months of the fiscal year ending December 31, 2025

Notes to the Interim Financial Statements (next)

**10. Intangible fixed assets**

	<u>Software program</u>	<u>Total</u>
<b>Historical Cost</b>		
Beginning Balance	59,564,895,987	59,564,895,987
Completed capital construction investment	-	-
<b>Ending Balance</b>	<u>59,564,895,987</u>	<u>59,564,895,987</u>
<i>Including:</i>		
Fully depreciated but still in use	-	-
<b>Accumulated depreciation</b>		
Beginning Balance	20,811,796,801	20,811,796,801
Depreciation during the year	2,971,369,794	2,971,369,794
<b>Ending Balance</b>	<u>23,783,166,595</u>	<u>23,783,166,595</u>
<b>Remaining Value</b>		
Beginning Balance	38,753,099,186	38,753,099,186
<b>Ending Balance</b>	<u>35,781,729,392</u>	<u>35,781,729,392</u>

The company's intangible fixed assets are the Pacs Software System:

This is a RIS – PACS medical image storage and transmission system that has been installed synchronously by the Company to serve medical examination and treatment, image diagnosis, and accompanying hardware installed at medical facilities (General Hospitals, Medical Centers of provinces/cities) according to the Agreement on cooperation in installation, trial use or business cooperation between the Company and medical facilities and has been accepted by the medical facilities and put into operation.

In some hospitals, there has been revenue, but due to the lack of specific and unified instructions on payment for technical services of diagnostic imaging based on the PACS system, the Company still does not have enough reliable basis to fully determine the economic benefits that will be obtained from this leasing and business cooperation. Currently, the Company is mainly collecting fees for providing maintenance services, maintenance of machinery and equipment as well as 24/24 technical support fees for the PACS system.

**11. Construction in progress**

	<u>Beginning Balance</u>	<u>Costs incurred during the period</u>	<u>Transferred to fixed assets during the period</u>	<u>Ending Balance</u>
Fixed asset purchases	20,691,002,908	4,030,862,562	(4,030,000,000)	20,691,865,470
Machine systems in hospitals	2,953,624,566	4,030,862,562	(4,030,000,000)	2,954,487,128
PACS System at Medical Centers	17,737,378,342	-	-	17,737,378,342
<b>Total</b>	<u>20,691,002,908</u>	<u>4,030,862,562</u>	<u>(4,030,000,000)</u>	<u>20,691,865,470</u>



**AMERICAN VIETNAMESE BIOTECH INC**

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

**INTERIM FINANCIAL REPORT**

First 6 months of the fiscal year ending December 31, 2025

**Notes to the Interim Financial Statements (next)****12. Long-term financial investment****a, Investment in Subsidiaries**

	Ending Balance		Beginning Balance	
	Original price	Preventive	Original price	Preventive
<i>Investment in subsidiaries</i>	<i>1,254,740,000,000</i>	<i>(56,612,625,329)</i>	<i>1,284,140,000,000</i>	<i>(36,715,580,781)</i>
Viet My Hospital Investment Joint Stock Company				
(Ownership ratio 83.33%)	250,000,000,000	(21,143,833,928)	250,000,000,000	(18,079,224,693)
Ha Long Kyoto Technology Development Joint Stock Company				
(Ownership ratio 99%)	108,900,000,000	(6,492,142,029)	108,900,000,000	(8,732,280,347)
Kyoto Bai Chay Clinic Joint Stock Company (Ownership ratio 98%)	49,000,000,000	(3,557,892,748)	49,000,000,000	-
Song Hau New Technology Application Research Joint Stock Company (Ownership ratio 98%)	147,000,000,000	-	147,000,000,000	-
Vietnam National Software Production Joint Stock Company (Ownership ratio 98%)	-	-	29,400,000,000	-
Ha Dong Clinic Joint Stock Company (Ownership ratio 98%)	77,420,000,000	(2,266,714,059)	77,420,000,000	-
Hoa Binh Clinic Joint Stock Company (Ownership ratio 98%)	122,500,000,000	-	122,500,000,000	(9,904,075,741)
Viet Tri Clinic Joint Stock Company (Ownership ratio 98%)	106,820,000,000	(15,055,788,286)	106,820,000,000	-
Gia Lam High-Tech Clinic Joint Stock Company (Ownership ratio 98%)	77,420,000,000	(4,428,476,444)	77,420,000,000	-
Medicare Can Tho Clinic Joint Stock Company (Ownership ratio 98%)	77,420,000,000	(1,538,670,896)	77,420,000,000	-
Medicare Hau Giang Clinic Joint Stock Company (Ownership ratio 98%)	77,420,000,000	(2,129,106,939)	77,420,000,000	-
Medicare Soc Trang Clinic Joint Stock Company (Ownership ratio 98%)	77,420,000,000	-	77,420,000,000	-
Medicare Nga Bay Clinic Joint Stock Company (Ownership ratio 98%)	77,420,000,000	-	77,420,000,000	-
Leopard Solutions Joint Stock Company (Ownership ratio 75%)	6,000,000,000	-	6,000,000,000	-
<b>Total</b>	<b><u>1,254,740,000,000</u></b>	<b><u>(56,612,625,329)</u></b>	<b><u>1,284,140,000,000</u></b>	<b><u>(36,715,580,781)</u></b>

# AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

## INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2025

Notes to the Interim Financial Statements (next)

### b, Investment in joint ventures and associates

These are investments in a chain of affiliated companies to establish clinics and testing centers across the country. The details of investments as at June 30, 2025 are presented below:

	Ending Balance		Actual capital contribution ratio	Beginning Balance		Actual capital contribution ratio
	Original price	Preventive		Original price	Preventive	
<i>Investment in joint ventures and associates</i>	<b>153,300,000,000</b>	<b>(1,466,800,688)</b>		<b>153,300,000,000</b>	<b>(921,745,039)</b>	
Golab Phap Van Laboratory Center Joint Stock Company	10,500,000,000	(85,622,015)	35%	10,500,000,000	(31,339,259)	35%
Famicare Phap Van Joint Stock Company (*)	10,500,000,000	-	35%	10,500,000,000	(12,655,367)	35%
Golab Go Vap Laboratory Center Joint Stock Company	10,500,000,000	(63,350,406)	35%	10,500,000,000	(29,123,121)	35%
Nghe An Clinic Joint Stock Company	10,500,000,000	(69,717,813)	35%	10,500,000,000	(35,878,195)	35%
Ba Dinh Clinic Joint Stock Company (*)	10,500,000,000	(570,966,723)	49%	10,500,000,000	(459,037,548)	49%
Golab Bac Lieu Laboratory Center Joint Stock Company	10,500,000,000	(74,480,965)	35%	10,500,000,000	(33,757,173)	35%
Golab Tien Giang Laboratory Center Joint Stock Company	10,500,000,000	(37,711,940)	35%	10,500,000,000	(22,457,100)	35%
Golab Binh Duong Laboratory Center Joint Stock Company (*)	10,500,000,000	(59,990,374)	35%	10,500,000,000	(12,406,284)	35%
Famicare Tuyen Quang Joint Stock Company	10,500,000,000	(31,463,807)	35%	10,500,000,000	(15,183,088)	35%
Golab Ha Giang Laboratory Center Joint Stock Company	14,700,000,000	(41,665,042)	49%	14,700,000,000	(3,748,697)	49%
Huu Nghi Medicare Clinic Joint Stock Company	14,700,000,000	(138,196,561)	49%	14,700,000,000	(116,686,997)	49%
Golab Ninh Binh Laboratory Center Joint Stock Company	14,700,000,000	(128,070,659)	49%	14,700,000,000	(66,206,661)	49%
Golab Vung Tau Laboratory Center Joint Stock Company (*)	14,700,000,000	(165,564,383)	49%	14,700,000,000	(83,265,549)	49%
<b>Total</b>	<b>153,300,000,000</b>	<b>(1,466,800,688)</b>		<b>153,300,000,000</b>	<b>(921,745,039)</b>	

(\*) These associate companies have been established but have not yet formed or hold insignificant assets for business operations.



**AMERICAN VIETNAMESE BIOTECH INC**

Totaddress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

**INTERIM FINANCIAL REPORT**

First 6 months of the fiscal year ending December 31, 2025

Notes to the Interim Financial Statements (next)

**13. Short-term trade payables**

	<u>Ending Balance</u>	<u>Beginning Balance</u>
Branch of Duy Minh Equipment Company Limited	-	650,444,922
Medical Communication Technology Joint Stock Company	100,000,000	-
JWB Co.,Ltd	298,643,120	298,643,120
Other suppliers	244,321,348	199,923,634
<b>Total</b>	<b>642,964,468</b>	<b>1,149,011,676</b>

**14. Taxes and amounts payable to the State**

	<u>Beginning balance of payables</u>	<u>Opening balance of receivables</u>	<u>Payables incurred during the period</u>	<u>Actual payments made during the period</u>	<u>Adjustments due to misclassification of sub-accounts</u>	<u>Ending balance of payables</u>
VAT on imported goods	887,523,548	-	19,235,023	(706,758,571)	(200,000,000)	-
Corporate income tax (CIT)	-	200,000,000	-	-	200,000,000	-
Personal income tax (PIT)	11,195,625	-	40,693,456	(39,960,920)	-	11,928,161
Other taxes	-	-	49,395,938	(49,395,938)	-	-
<b>Total</b>	<b>898,719,173</b>	<b>200,000,000</b>	<b>109,324,417</b>	<b>(796,115,429)</b>	<b>-</b>	<b>11,928,161</b>

The company's tax finalization will be subject to inspection by the tax authorities. Since the application of laws and regulations regarding taxes on various types of transactions can be interpreted in multiple ways, the tax amount presented in the financial statements may be subject to change based on the decision of the tax authorities.

**Value-Added Tax**

The company pays value-added tax (VAT) according to the credit-invoice method. The VAT rate is as follows:

- Revenue from the sale of medical supplies and equipment 5%
- Revenue from providing testing, imaging, and diagnostic services in collaboration with hospitals Exempt from tax
- Other activities 8%, 10%

**AMERICAN VIETNAMESE BIOTECH INC**

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

**INTERIM FINANCIAL REPORT**

First 6 months of the fiscal year ending December 31, 2025

**Notes to the Interim Financial Statements (next)****Corporate income tax**

Corporate income tax is calculated based on taxable income for the year, with an applicable tax rate of 20%.

**Other type of taxes**

Other taxes, which the company declares and pays according to regulations.

**15. Short-term payable expenses**

	<u>Ending Balance</u>	<u>Beginning Balance</u>
Interest expense payable	21,732,252,612	19,438,461,246
Other short-term payable expenses	-	322,000,000
<b>Total</b>	<b><u>21,732,252,612</u></b>	<b><u>19,760,461,246</u></b>

**16. Other short-term payables**

	<u>Ending Balance</u>	<u>Beginning Balance</u>
Social Insurance	82,305,000	-
Health Insurance	14,814,900	-
Unemployment Insurance	6,584,400	-
Occupational Accident and Disease Insurance	1,645,600	-
Dividends payable (*)	75,924,090,000	75,924,090,000
Other short-term payables	7,180,000	7,180,000
<b>Total</b>	<b><u>76,036,619,900</u></b>	<b><u>75,931,270,000</u></b>

(\*) The 2019 dividend must be paid to shareholders according to the shareholder list as of January 12, 2021. Resolution No. 2502/NQ-HĐQT dated February 25, 2025 of the Board of Directors on changing the time for paying dividends in 2019, accordingly the time for paying dividends is as follows: Payment of the first installment on January 28, 2026; Payment of the second installment on July 28, 2026.

Reason for change: The company is expanding its production and business activities and investing in equipment and machinery for important projects. To ensure progress, the company uses available capital to order necessary equipment.

**17. Short-term loans and finance leases**

	<u>Ending Balance</u>		<u>Beginning Balance</u>	
	<u>Value</u>	<u>Number of debtors</u>	<u>Value</u>	<u>Number of debtors</u>
<b>Short term bank loans</b>				
BVBank (*)	23,126,095,827	23,126,095,827	24,625,095,827	24,625,095,827
<b>Total</b>	<b><u>23,126,095,827</u></b>	<b><u>23,126,095,827</u></b>	<b><u>24,625,095,827</u></b>	<b><u>24,625,095,827</u></b>

(\*) Loan under Credit Contract No. 0041900059900 dated November 28, 2019; Amendment and Supplement Agreement dated July 6, 2021 regarding adjustment of the principal repayment schedule. Loan amount: VND 40,000,000,000; Purpose of the loan: Purchase of medical machinery and equipment for production and business operations; Interest rate: 11.5% per annum; Loan term: 48 months. Collateral: medical machinery and equipment under Movable Asset Mortgage Contract No. 0041900060000 dated November 28, 2019.



**AMERICAN VIETNAMESE BIOTECH INC**

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

**INTERIM FINANCIAL REPORT**

First 6 months of the fiscal year ending December 31, 2025

**Notes to the Interim Financial Statements (next)**

As of the issuance date of this report, the above loan is overdue. The extension request period stated in Official Letter No. 05/2024/CV-AMV of the Company was October 2024, and it was approved by BVBank in Official Letter No. 212/2024/BVbank/CV-QL&THN dated April 9, 2024. However, as of now, the Company has not yet fully repaid the aforementioned principal amount and is continuing to work with the Bank to request an extension.

Details of short-term loans incurred during the period as follows:

	Beginning Balance	Amount of loan incurred during the period	Loan amount repaid during the year	Ending Balance
BVBank (*)	24,625,095,827	-	(1,499,000,000)	23,126,095,827
<b>Total</b>	<b>24,625,095,827</b>	<b>-</b>	<b>(1,499,000,000)</b>	<b>23,126,095,827</b>

**18. Owner's Equity****a, Statement of Changes in Owners' Equity**

	Owner's equity	Capital surplus	Profit after tax not distributed	Total
Last year's opening number	1,311,056,500,000	(395,300,000)	246,895,237,887	1,557,556,437,887
Profit in the previous year	-	-	(12,651,723,096)	(12,651,723,096)
<b>Last year ending balance</b>	<b>1,311,056,500,000</b>	<b>(395,300,000)</b>	<b>234,243,514,791</b>	<b>1,544,904,714,791</b>
Beginning balance of this year	1,311,056,500,000	(395,300,000)	234,243,514,791	1,544,904,714,791
Profit for this period	-	-	(10,395,144,499)	(10,395,144,499)
<b>This period's ending balance</b>	<b>1,311,056,500,000</b>	<b>(395,300,000)</b>	<b>223,848,370,292</b>	<b>1,534,509,570,292</b>

**b, Breakdown of capital contributions by owners:**

	Ending Balance		Beginning Balance	
	Value	Ownership ratio	Value	Ownership ratio
Other shareholders	1,311,056,500,000	100,00%	1,311,056,500,000	100,00%
<b>Total</b>	<b>1,311,056,500,000</b>	<b>100,00%</b>	<b>1,311,056,500,000</b>	<b>100,00%</b>

**c, Stocks**

	Ending Balance	Beginning Balance
Number of shares registered for issuance	131.105.650	131.105.650
Number of shares issued/sold to the public	131.105.650	131.105.650
- Common shares	131.105.650	131.105.650
- Preferred shares	-	-
Number of outstanding shares	131.105.650	131.105.650
- Common shares	131.105.650	131.105.650
- Preferred shares	-	-

Outstanding shares face value: 10,000 VND.

**AMERICAN VIETNAMESE BIOTECH INC**

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

**INTERIM FINANCIAL REPORT**

First 6 months of the fiscal year ending December 31, 2025

Notes to the Interim Financial Statements (next)

**VI. ADDITIONAL INFORMATION ON ITEMS PRESENTED IN THE INTERIM STATEMENT OF INCOME****1. Revenue from sales and service provision**

	Accumulated from the beginning of the year to the end of this period	
	<u>This year</u>	<u>This year</u>
Revenue from sales of goods and provision of services	6,427,336,856	33,117,279,215
Revenue deductions	-	-
<i>Returned goods</i>	-	-
<b>Net revenue from sales and services</b>	<b><u>6,427,336,856</u></b>	<b><u>33,117,279,215</u></b>

**2. Cost of goods sold**

	Accumulated from the beginning of the year to the end of this period	
	<u>This year</u>	<u>This year</u>
Cost of goods sold, services provided	7,366,727,194	32,299,544,827
<b>Total</b>	<b><u>7,366,727,194</u></b>	<b><u>32,299,544,827</u></b>

**3. Financial income**

	Accumulated from the beginning of the year to the end of this period	
	<u>This year</u>	<u>This year</u>
Deposit interest, loan interest	364,401	186,282
Dividends, profits shared	17,009,339,331	5,000,000,000
<b>Total</b>	<b><u>17,009,703,732</u></b>	<b><u>5,000,186,282</u></b>

**4. Financial expenses**

	Accumulated from the beginning of the year to the end of this period	
	<u>This year</u>	<u>This year</u>
Interest expense	2,293,791,366	3,034,589,990
Provision/(Reversal) of investment loss provision	20,442,100,197	13,955,084,469
<b>Total</b>	<b><u>22,735,891,563</u></b>	<b><u>16,989,674,459</u></b>

**5. Cost of sales**

	Accumulated from the beginning of the year to the end of this period	
	<u>This year</u>	<u>This year</u>
Employee costs	133,333,326	133,333,332
Outsourcing service costs	2,080,000	17,217,375
<b>Total</b>	<b><u>135,413,326</u></b>	<b><u>150,550,707</u></b>



**AMERICAN VIETNAMESE BIOTECH INC**

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

**INTERIM FINANCIAL REPORT**

First 6 months of the fiscal year ending December 31, 2025

**Notes to the Interim Financial Statements (next)****6. Business management costs**

	Accumulated from the beginning of the year to the end of this period	
	This year	This year
Employee costs	2,793,470,685	1,164,362,725
Office supplies costs	13,281,999	20,590,908
Fixed asset depreciation costs	2,996,214	2,996,214
Taxes, fees and charges	7,000,000	6,000,000
Provision/(Reversal) of provision for doubtful debts	-	171,239,844
Outsourcing service costs	874,939,576	447,084,670
Other costs	286,196	-
<b>Total</b>	<b>3,691,974,670</b>	<b>1,812,274,361</b>

**7. Other income**

	Accumulated from the beginning of the year to the end of this period	
	This year	This year
Gain on disposal of fixed assets	140,000,000	-
Other income	217,607	-
<b>Total</b>	<b>140,217,607</b>	<b>-</b>

**8. Other costs**

	Accumulated from the beginning of the year to the end of this period	
	This year	This year
Penalty for late payment of tax and insurance	42,395,941	32,940,246
<b>Total</b>	<b>42,395,941</b>	<b>32,940,246</b>

**9. Current corporate income tax expense**

Corporate income tax payable during the period is estimated as follows:

	Accumulated from the beginning of the year to the end of this period	
	This year	This year
Total accounting profit before tax	(10,395,144,499)	(13,167,519,103)
Adjustments to increase or decrease accounting profit to determine profit subject to corporate income tax:	(15,021,112,825)	(3,021,229,189)
- Increase adjustments	1,988,226,506	1,978,770,811
<i>Depreciation of fixed assets not serving production and business</i>	1,945,830,565	1,945,830,565
<i>Penalty for late payment of tax and insurance</i>	42,395,941	32,940,246
- Adjustments for reduction	(17,009,339,331)	(5,000,000,000)
<i>Dividends, profits shared</i>	(17,009,339,331)	(5,000,000,000)
<b>Taxable income</b>	<b>(25,416,257,324)</b>	<b>(16,188,748,292)</b>
<b>Taxable income</b>	<b>(25,416,257,324)</b>	<b>(16,188,748,292)</b>
<b>Corporate income tax rate</b>	<b>20%</b>	<b>20%</b>
<b>Total Corporate Income Tax payable</b>	<b>-</b>	<b>-</b>

**AMERICAN VIETNAMESE BIOTECH INC**

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

**INTERIM FINANCIAL REPORT**

First 6 months of the fiscal year ending December 31, 2025

**Notes to the Interim Financial Statements (next)**

**10. Basic earnings per share**

Enterprises do not calculate this indicator on the separate financial statements because according to the provisions of accounting standard No. 30 on "Earnings per share", in case an Enterprise has to prepare both separate financial statements and consolidated financial statements, it only has to present information on earnings per share according to the provisions of this standard on the consolidated financial statements.

**11. Expenses by category**

	Accumulated from the beginning of the year to the end of this period	
	This year	This year
Cost of raw materials	48,282,000	20,590,908
Labor costs	2,926,804,011	1,297,696,057
Fixed asset depreciation costs	5,277,338,239	5,023,460,818
Taxes, fees and charges	7,000,000	6,000,000
Provision/(Reversal) of provision for doubtful debts	-	171,239,844
Outsourcing service costs	934,519,576	464,302,045
Other costs	286,196	-
<b>Total</b>	<b>9,194,230,022</b>	<b>6,983,289,672</b>

**VII. OTHER INFORMATION****1. Information about related parties**

Stakeholders of the Enterprise include: key management members, individuals related to key management members and other stakeholders.

**A, Transactions and balances with key management members and individuals related to key management members**

Key management members include: members of the Board of Directors and members of the Executive Board (Board of Directors, Chief Accountant). Individuals related to key management members are close family members of key management members.

*Key Management Members' Compensation:*

	Current period	Previous period
Mrs. Dang Nhi Nuong	121,000,000	121,000,000

*During the period, the unit did not have any transactions with related parties.*

**B, Transactions with other related parties**

Other related parties to the Enterprise include: subsidiaries, affiliated companies, individuals with direct or indirect voting rights in the Enterprise and close members of their families, enterprises managed by key management personnel and individuals with direct or indirect voting rights of the Enterprise and close members of their families.

**Related parties include:**

	Relationship
Viet My Hospital Investment Joint Stock Company	Subsidiary
Ha Long Kyoto Technology Development Joint Stock Company	Subsidiary
Bai Chay Kyoto Clinic Joint Stock Company	Subsidiary
Song Hau New Technology Application Research Joint Stock Company	Subsidiary
Vietnam National Software Production Joint Stock Company	Subsidiary



**AMERICAN VIETNAMESE BIOTECH INC**

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

**INTERIM FINANCIAL REPORT**

First 6 months of the fiscal year ending December 31, 2025

**Notes to the Interim Financial Statements (next)**

<b>Related parties include:</b>	<b>Relationship</b>
Viet My Hospital Investment Joint Stock Company	Subsidiary
Ha Long Kyoto Technology Development Joint Stock Company	Subsidiary
Bai Chay Kyoto Clinic Joint Stock Company	Subsidiary
Song Hau New Technology Application Research Joint Stock Company	Subsidiary
Ha Dong Clinic Joint Stock Company	Subsidiary
Hoa Binh Clinic Joint Stock Company	Subsidiary
Viet Tri Clinic Joint Stock Company	Subsidiary
Gia Lam High-Tech Clinic Joint Stock Company	Subsidiary
Can Tho Medicare Clinic Joint Stock Company	Subsidiary
Hau Giang Medicare Clinic Joint Stock Company	Subsidiary
Soc Trang Medicare Clinic Joint Stock Company	Subsidiary
Nga Bay Medicare Clinic Joint Stock Company	Subsidiary
Leopard Solutions Joint Stock Company	Subsidiary
Golab Vung Tau Test Center Joint Stock Company	Associate company
Huu Nghi Medicare Clinic Joint Stock Company	Associate company
Golab Ninh Binh Test Center Joint Stock Company	Associate company
Golab Ha Giang Test Center Joint Stock Company	Associate company
Golab Phap Van Test Center Joint Stock Company	Associate company
Famicare Phap Van Joint Stock Company	Associate company
Famicare Tuyen Quang Joint Stock Company	Associate company
Nghe An Clinic Joint Stock Company	Associate company
Ba Dinh Clinic Joint Stock Company	Associate company
Golab Bac Lieu Test Center Joint Stock Company	Associate company
Golab Tien Giang Test Center Joint Stock Company	Associate company
Golab Binh Duong Test Center Joint Stock Company	Associate company
Golab Go Vap Testing Center Joint Stock Company	Associate company

*Transactions with other related parties*

The main transactions during the period between the Company and other related parties are as follows:

	<b>Accumulated from the beginning of the year to the end of this period</b>	
	<b>This year</b>	<b>This year</b>
<b>Viet Tri Clinic Joint Stock Company</b>		
Advance collections	-	23,000,000,000
<b>Golab Binh Duong Testing Center Joint Stock Company</b>		
Capital support received	500,000,000	-
<b>Hau Giang Medicare Clinic Joint Stock Company</b>		
Payables for goods purchased	4,231,500,000	-
Payments for goods purchased	4,231,500,000	-
<b>Vietnam National Software Production Joint Stock Company</b>		
Dividend receivable	17,009,339,331	5,000,000,000
Receive dividends and profits	22,009,339,331	5,000,000,000
<b>Golab Phap Van Laboratory Center Joint Stock Company</b>		

**AMERICAN VIETNAMESE BIOTECH INC**

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

**INTERIM FINANCIAL REPORT**

First 6 months of the fiscal year ending December 31, 2025

**Notes to the Interim Financial Statements (next)**

	Accumulated from the beginning of the year to the end of this period	
	<u>This year</u>	<u>This year</u>
Receivables from capital support	-	2,500,000,000
<b>Famicare Phap Van Joint Stock Company</b>		
Receivables from capital support	-	2,500,000,000
<b>Huu Nghi Medicare Clinic Joint Stock Company</b>		
Capital contribution during the period	-	1,763,500,000
<b>Golab Ninh Binh Testing Center Joint Stock Company</b>		
Capital contribution during the period	-	1,000,000,000
<b>Golab Phap Van Testing Center Joint Stock Company</b>		
Capital contribution during the period	-	10,500,000,000
<b>Famicare Phap Van Joint Stock Company</b>		
Capital contribution during the period	-	10,500,000,000
<b>Golab Go Vap Testing Center Joint Stock Company</b>		
Capital contribution during the period	-	10,500,000,000
<b>Nghe An Clinic Joint Stock Company</b>		
Capital contribution during the period	-	1,000,000,000
<b>The company's transactions of sales and service provision with related parties during the period are as follows:</b>		
<b>Sales and service provision:</b>		
Golab Phap Van Testing Center Joint Stock Company	38,500,000	-
Golab Ninh Binh Test Center Joint Stock Company	38,500,000	-
Nghe An Clinic Joint Stock Company	38,500,000	-
Golab Bien Hoa Testing Center Joint Stock Company	38,500,000	-
<b>Cash received from sales and service provision:</b>		
Huu Nghi Medicare Clinic Joint Stock Company	244,200,000	-
Golab Phap Van Test Center Joint Stock Company	242,000,000	-
Golab Hai Phong Test Center Joint Stock Company	2,932,070,200	-
Golab Hai Duong Test Center Joint Stock Company	7,159,494,700	-
Golab Hung Yen Test Center Joint Stock Company	7,013,194,700	-
Golab Quang Binh Test Center Joint Stock Company	2,913,210,200	-
Golab Dong Thap Test Center Joint Stock Company	2,768,270,200	-
Golab Vinh Long Test Center Joint Stock Company	2,768,270,200	-
Golab An Giang Test Center Joint Stock Company	2,725,370,200	-
Famicare Kien Giang Joint Stock Company	5,250,384,500	-
Golab Kien Giang Test Center Joint Stock Company	6,767,870,200	-
Golab Bac Ninh Test Center Joint Stock Company	7,128,594,700	-
Golab Vinh Phuc Test Center Joint Stock Company	7,364,884,500	-
Golab Ninh Binh Test Center Joint Stock Company	42,900,000	-



**AMERICAN VIETNAMESE BIOTECH INC**

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City  
INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2025

Notes to the Interim Financial Statements (next)

	Accumulated from the beginning of the year to the end of this period	
	This year	This year
Golab Ha Tinh Test Center Joint Stock Company	4,385,784,500	-
Famicare Quang Binh Joint Stock Company	4,315,384,500	-
Golab Bien Hoa Test Center Joint Stock Company	4,042,500,000	-
Golab Gia Lai Test Center Joint Stock Company	2,832,870,200	-
Famicare Vinh Long Joint Stock Company	7,075,694,700	-
Golab Tan An Test Center Joint Stock Company	2,822,420,200	-
Viet My Hospital Investment Joint Stock Company	2,835,000,000	-

At the end of the accounting period, debts with related parties are presented in detail in notes V.3; V.4 and V.11./.

**2. Fair value of financial assets and liabilities**

	Book value		Fair value	
	Ending Balance	Beginning Balance	Ending Balance	Beginning Balance
<b>Financial assets</b>				
Cash and cash equivalents	3,733,061,864	2,123,348,100	3,733,061,864	2,123,348,100
Accounts receivable	5,804,571,415	153,111,019,347	5,804,571,415	153,111,019,347
Other receivables	194,031,880,893	6,107,640,662	194,031,880,893	6,107,640,662
<b>Total</b>	<b>203,569,514,172</b>	<b>161,342,008,109</b>	<b>203,569,514,172</b>	<b>161,342,008,109</b>
<b>Financial liabilities</b>				
Loans and Debts	23,126,095,827	24,625,095,827	23,126,095,827	24,625,095,827
Payable to seller	642,964,468	1,149,011,676	642,964,468	1,149,011,676
Other payables	97,768,872,512	95,691,731,246	97,768,872,512	95,691,731,246
<b>Total</b>	<b>121,537,932,807</b>	<b>121,465,838,749</b>	<b>121,537,932,807</b>	<b>121,465,838,749</b>

The fair value of financial assets and financial liabilities is reflected at the amount at which the financial instruments could be exchanged in a current transaction between knowledgeable and willing parties.

The Company uses the following methods and assumptions to estimate fair value:

- The fair value of cash and cash equivalents, trade receivables, loans, other receivables, borrowings, trade payables and other short-term payables is equivalent to the book value (net of provisions for estimated uncollectibility) of these items due to their short maturity.
- The fair value of loans, trade receivables, other receivables, borrowings, trade payables and other long-term payables, held-to-maturity investments that are not listed on the stock market and do not have a trading price announced by 3 securities companies is estimated by discounting cash flows at the interest rate applicable to debts with similar characteristics and remaining maturity.

**3. Credit risk**

Credit risk is the risk that a party to a contract will not be able to perform its obligations resulting in financial loss to the Company.

The Company is exposed to credit risk from its operating activities (primarily trade receivables) and financing activities (bank deposits, loans and other financial instruments).

## AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City  
INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2025

Notes to the Interim Financial Statements (next)

### *Accounts receivable*

The Company minimizes credit risk by only dealing with financially sound entities, requiring letters of credit to be opened for entities that are trading for the first time or have no information on their financial capabilities, and having accounts receivable staff regularly monitor receivables to urge collection. On this basis, and the Company's receivables are related to many different customers, credit risk is not concentrated on a particular customer.

### *Depositechorow*

Most of the bank deposits ofThe company is deposited in large, reputable banks in Vietnam. The company finds that the level of concentration of credit risk for bank deposits is low.

## 4. Riskliquidity risk

Liquidity risk is the riskThe company had difficulty meeting its financial obligations due to lack of funds.

The Board of Directors has ultimate responsibility for liquidity risk management. The Company's liquidity risk arises primarily from the mismatch of maturities between its financial assets and financial liabilities.

The Company manages liquidity risk by maintaining an appropriate level of cash and cash equivalents and borrowings at levels deemed necessary by the Board.The leadership considers it sufficient to meet the operational needs of theThe company aims to minimize the impact of cash flow fluctuations.

The maturity of financial liabilities based on undiscounted contractual payments is as follows:

	1 year or less	Over 1 year to 5 years	Over 5 years	Total
<b>Ending Balance</b>				
Loans and Debts	23,126,095,827	-	-	23,126,095,827
Payable to seller	642,964,468	-	-	642,964,468
Other payables	97,768,872,512	-	-	97,768,872,512
<b>Total</b>	<b>121,537,932,807</b>	<b>-</b>	<b>-</b>	<b>121,537,932,807</b>
<b>Beginning Balance</b>				
Loans and Debts	24,625,095,827	-	-	24,625,095,827
Payable to seller	1,149,011,676	-	-	1,149,011,676
Other payables	95,691,731,246	-	-	95,691,731,246
<b>Total</b>	<b>121,465,838,749</b>	<b>-</b>	<b>-</b>	<b>121,465,838,749</b>

The Company believes that the concentration of risk with respect to debt repayment is low. The Company is able to repay its debts when they fall due from cash flows from operations and proceeds from maturing financial assets.

## 5. Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk includes three types: currency risk, interest rate risk and other price risk.

The sensitivity analyses presented below are based on a constant value of net debt, with the ratio of fixed-rate debt to floating-rate debt remaining constant.



## AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

### INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2025

#### Notes to the Interim Financial Statements (next)

##### *Foreign exchange risk*

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.

##### *Interest rate risk*

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

Interest rate risk of Company mainly related to money and loans.

The Company manages interest rate risk by analyzing market conditions to obtain the most favorable interest rates while remaining within its risk management limits.

##### *Other price risks*

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices other than changes in interest rates and foreign exchange rates.

#### 6. Significant events during the accounting period affecting the financial statements

- American VietNameese Biotech INC ("AMV") with many years of experience in the medical field: providing machinery and equipment systems, supplying consumables,... Facing the increasing demand for health care services, cancer screening and home health care, learning from the infusion center model - built and operated according to Japan's international safety standards - specializing in providing drug, vitamin, protein, therapy and water infusion services to improve patient health, is gradually becoming a popular trend in many countries such as Japan, the US, Thailand. However, in Vietnam, this model is still quite new and has not been widely deployed. At the same time, after reviewing and evaluating the overall mobile examination vehicle project, investment project, joint venture linking medical image archiving and transmission systems (PACS system) with hospitals that the company previously pursued, it did not meet expectations as expected. Therefore, the company boldly divested all or part of those projects, the Company has determined a strategy to strongly develop the clinic and infusion center model in the coming time. This business strategy was approved at the 2024 Annual General Meeting of Shareholders. At present, the Company is continuing to carry out the necessary procedures to put into operation a chain of clinics across 34 provinces and cities nationwide, with the expectation of providing early and reliable diagnostic testing at the most cost-effective level through its network of testing centers.

- Resolution of the Board of Directors No. 0601/2025/NQ-HĐQT dated January 6, 2025 and Resolution of the Board of Directors No. 1701/2025/NQ-HĐQT dated January 17, 2025 on receiving the transfer of VND 204,227,000,000 of contributed capital at Phu Tho Provincial General Hospital, from Sara Vietnam Joint Stock Company. The transfer value from Sara Vietnam Joint Stock Company under contract No. 01/2025/HĐCN/SARA-VIETMY dated February 15, 2025 is VND 204,227,000,000. Up to now, the Company has paid the entire amount of VND 204,227,000,000. However, according to Resolution of the Board of Directors No. 1604/2025/NQ-HĐQT dated April 16, 2025, the Company decided to withdraw capital early from Phu Tho Provincial General Hospital, the capital withdrawal plan is from 2025 to 2028. Up to now, the Hospital has transferred 17,5 billion to the company.

## AMERICAN VIETNAMESE BIOTECH INC

Totalress: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

### INTERIM FINANCIAL REPORT

First 6 months of the fiscal year ending December 31, 2025

Notes to the Interim Financial Statements (next)

#### 7. Comparison information

Comparative figures on the Interim Balance Sheet are the figures on the Balance Sheet as of December 31, 2024 audited by Nhan Tam Viet Auditing Company Limited. Comparative figures on the Interim Income Statement and Interim Cash Flow Statement are the figures on the Interim Income Statement and Interim Cash Flow Statement for the first 6 months of the fiscal year ended December 31, 2024 audited by Nhan Tam Viet Auditing Company Limited.

Prepared on 28 August, 2025

Prepared by .



\_\_\_\_\_  
Nguyen Thu Huyen

Chief Accountant



\_\_\_\_\_  
Dang Thi Thanh Tuyen

Director



\_\_\_\_\_  
Dang Nhi Nuong